

Answering reviewers

Reviewer 1

Comment- "I read with great interest the manuscript entitled "Medicinal nicotine in COVID-19 ARDS, the New Corticosteroid". It is a novel concept and the article is well written. I have only 2 suggestions 1. There is some repetition in the discussion section, which can be avoided 2. In the concluding remarks it must be mentioned that there is presently a lack of literature regarding the use of nicotine in COVID 19 patients and it must be studied first before being applied routinely."

Response- Thank you for the insightful comment. Following changes were made-

1. Several repetitions as you mentioned have been removed.
2. A statement at the end of the discussion emphasises that the use of nicotine in COVID ARDS has not been studied, and further data is needed before routine use.

Fei-Yan Lin (online science editor)

Specific Comments To Authors: "This review summarizes the use of immunomodulators in the treatment of COVID-19 induced acute respiratory distress syndrome. But there is little research on nicotine and CAP in alleviating inflammation in COVID-19 acute hypoxic respiratory failure, and this potential needs to be further validated. The abstract is too simple to reflect the main point of the article. Scientific Quality: Grade C (Good) Language Quality: Grade B (Minor language polishing) Conclusion: Major revision"

Response- Thank you for your insightful comment. Following changes were made, based on your recommendation-

1. More details of the CAP circuit have been explained in the abstract.
2. It has been emphasised that clinical evidence in the setting of COVID ARDS is currently lacking.

Thank you

Farrukh Ahmad MD